AC Immune reports early Phase 1 data for NLRP3 inhibitor ACI-19764
Tweet Send to a Friend
AC Immune SA (NASDAQ: ACIU) announced preliminary results from a Phase 1 first-in-human clinical study of ACI-19764, an oral small ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
